Identify Your Lead Solid Form Early To Reduce Timelines And Downstream Costs

Devoting early-phase resources to finding the lead solid form of an active pharmaceutical ingredient (API) can save you time and resources down the road. Lonza Small Molecules recently hosted a webinar entitled, Solid Form Screening of Active Pharmaceutical Ingredients that highlighted the benefits of solid form understanding and screening on a drug’s development cycle. Throughout the presentation, Abhijeet S. Sinha, Manager of Solid Form Services (SFS), provided a breakdown of different solid forms, the workflow of solid form screenings, and a Lonza SFS client case study focused on polymorphs of a late-stage API.

The scope of solid form screening is dependent on the phase of drug development. In early development, SFS can conduct several screens, including polymorph, salt, and cocrystal screens, as well as characterization and risk assessments to nominate the lead crystalline form. In later phases, SFS can conduct additional risk assessment screens and troubleshoot your crystallization process development. Download the full article to review attendee questions and Abhijeet’s answers on how to nominate a lead form, when to utilize a salt screen, and other solid form strategies.